130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)
References (0)
Cited by (0)
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.